SCHEMBL189532

SCHEMBL189532

O=C(O)CC1CC2CCC1C2

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.54
NPC1 O15118 1/20 0.54
RAB9A P51151 1/20 0.54
KMT2A Q03164 1/20 0.54
HSD11B1 P28845 1/20 0.48
SLC6A12 P48065 3/20 0.46
SLC6A11 P48066 3/20 0.46
SLC6A13 Q9NSD5 3/20 0.46
P2RX7 Q99572 1/20 0.43
HPGD P15428 1/20 0.43
POLB P06746 1/20 0.41
LMNA P02545 2/20 0.40
ALDH1A1 P00352 2/20 0.39
KDM4E B2RXH2 1/20 0.39
TP53 P04637 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
HSD17B10 Q99714 1/20 0.39
SIRT5 Q9NXA8 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12832578 1.00 MEN1 (0.54) MEN1NPC1RAB9AKMT2AHSD11B1
SCHEMBL3915502 1.00 MEN1 (0.54) MEN1NPC1RAB9AKMT2AHSD11B1
SCHEMBL3915501 1.00 MEN1 (0.54) MEN1NPC1RAB9AKMT2AHSD11B1
SCHEMBL7269130 1.00 MEN1 (0.54) MEN1NPC1RAB9AKMT2AHSD11B1
SCHEMBL5449679 1.00 MEN1 (0.54) MEN1NPC1RAB9AKMT2AHSD11B1
SCHEMBL1527314 1.00 MEN1 (0.54) MEN1NPC1RAB9AKMT2AHSD11B1
SCHEMBL1527315 1.00 MEN1 (0.54) MEN1NPC1RAB9AKMT2AHSD11B1
SCHEMBL20573107 1.00 MEN1 (0.54) MEN1NPC1RAB9AKMT2AHSD11B1
SCHEMBL20573120 1.00 MEN1 (0.54) MEN1NPC1RAB9AKMT2AHSD11B1
SCHEMBL11611772 0.89 SLC6A12 (0.48) MEN1NPC1RAB9AKMT2AHSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 945 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4661890-A1 PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS Purdue Research Foundation (US) 2025-12-17 EP claimed
WO-2024167565-A1 PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS PURDUE RESEARCH FOUNDATION (US) 2024-08-15 WO claimed
US-10072043-B2 Inhibitors of protein tyrosine phosphatases INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2018-09-11 US claimed
US-20160176922-A1 INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES Indiana University Research and Technology Corpora tion (US) 2016-06-23 US claimed
US-9217012-B2 Inhibitors of protein tyrosine phosphatases INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2015-12-22 US claimed
CN-101205469-B Liquid crystal aligning agent, liquid crystal aligning film, liquid crystal display element and optical components JSR CORP 2013-03-27 CN claimed
CN-101679633-B Resin composition for forming heat-cured film NISSAN CHEMICAL IND LTD 2012-09-19 CN claimed
US-20120088720-A1 INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATI (US) 2012-04-12 US claimed
CN-101266363-B Liquid crystal orientating agent and liquid crystal display element JSR CORP 2011-08-31 CN claimed
WO-2010118241-A2 INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (US) 2010-10-14 WO claimed
US-20050090690-A1 Process for preparing tetra-amide compounds XEROX CORPORATION 2005-04-28 US claimed
US-20030082830-A1 Synthesis of combinatorial libraries of compounds reminiscent of natural products NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2003-05-01 US claimed
US-6492531-B1 THE INVENTION CONCERNS CHOLECYSTOKININ (CCK) ANTAGONISTS USEFUL IN THE TREATMENT OF COGNITIVE DISORDERS. ESPECIALLY USEFUL ARE CCK.SUB.B ANTAGONISTS SUCH AS CI-988. WARNER-LAMBERT COMPANY 2002-12-10 US claimed
US-20020141952-A1 Regulating the melanin content of mammalian melanocytes by administering alcohols, diols, triols and their analogues APPLIED GENETICS INCORPORATED DERMATICS 2002-10-03 US claimed
WO-2002051395-A1 TREATMENT OF NEURODEGENERATIVE DISEASES CODON PHARMACEUTICALS, INC. (US) 2002-07-04 WO claimed
CN-1306222-A Liquid crystal directional membrane and liquid crystal displaying componnet JSR CORP (JP) 2001-08-01 CN claimed
WO-2000006525-A9 SYNTHESIS OF COMBINATORIAL LIBRARIES OF COMPOUNDS REMINISCENT OF NATURAL PRODUCTS HARVARD COLLEGE (US) 2000-04-20 WO claimed
WO-2000006525-A2 SYNTHESIS OF COMBINATORIAL LIBRARIES OF COMPOUNDS REMINISCENT OF NATURAL PRODUCTS PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2000-02-10 WO claimed
WO-1999043356-A1 ANTIBIOTIC-LIGAND CONJUGATES AND METHODS OF USE THEREOF HSC RESEARCH DEVELOPMENT LIMITED PARTNERSHIP (CA) 1999-09-02 WO claimed
WO-1998055085-A1 PHARMACEUTICAL COMPOSITIONS AND METHODS CODON PHARMACEUTICALS, INC. (US) 1998-12-10 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10072043-B2 Inhibitors of protein tyrosine phosphatases PTPRCAP, PTPRF, PTPRS MEN1 4428/4885NPC1 3543/4885RAB9A 2114/4885
US-20020141952-A1 Regulating the melanin content of mammalian melanocytes by administering alcohols, diols, triols and their analogues TYR, MITF, MC1R MEN1 540/4885NPC1 2390/4885RAB9A 1063/4885
US-20160176922-A1 INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES PTPRCAP, PTPRF, PTPRS MEN1 4428/4885NPC1 3543/4885RAB9A 2114/4885
US-20050090690-A1 Process for preparing tetra-amide compounds TAF9, TAF5, TAF1 MEN1 1466/4885NPC1 3601/4885RAB9A 789/4885
US-20120088720-A1 INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES PTPRCAP, PTPRF, PTPRS MEN1 4428/4885NPC1 3543/4885RAB9A 2114/4885
US-20030082830-A1 Synthesis of combinatorial libraries of compounds reminiscent of natural products TKFC, NISCH, PTGIS MEN1 4825/4885NPC1 4176/4885RAB9A 4699/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.